on ABIVAX (EPA:ABVX)
Helikon increases its investment in ABIVAX
Helikon Investments Limited, through its Helikon Long Short Equity Fund Master ICAV, recently increased its stake in ABIVAX. This fund crossed the 5% threshold of ABIVAX's share capital, holding 5.02% as of September 24, 2026, through a market acquisition.
On September 25, the fund further strengthened its position, reaching 5.16% of the share capital and 5.09% of the voting rights. This continued increase resulted in the fund holding 6.22% of the share capital, representing 6.13% of the voting rights, as of October 8, for a total of 5,426,529 shares.
The shares held also result from equity swap contracts, influencing the reported figures. These increases reflect Helikon's targeted investment strategy on ABIVAX.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news